Precigen Inc. Stock
Price
Target price
?
?
-0.900%
-0.04
-0.900%
-
07:33 / Stuttgart Stock Exchange
WKN: A2PZG1 / Name: Precigen / Stock / Electrical Utilities & IPPs / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Precigen Inc. Stock
The price for the Precigen Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.040 (-0.900%).
Pros and Cons of Precigen Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Precigen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Precigen Inc. | -0.900% | -7.469% | 9.314% | 181.922% | 20.151% | 333.010% | -5.227% |
| Mighty River Power Ltd | 0.000% | -0.625% | -4.790% | 3.247% | 1.923% | -11.173% | -15.873% |
| A2A SpA | -0.550% | 0.383% | 3.606% | 7.777% | 2.569% | 41.629% | 35.519% |
| CEMIG ADR | -0.540% | 5.587% | 6.180% | 18.868% | 10.526% | -16.372% | 27.971% |
News
What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?
On July 1, 2026, Precigen (NASDAQ:PGEN) Chief Financial Officer Harry Thomasian Jr. reported the sale of 200,000 shares of common stock in multiple open-market transactions between June 29 and July
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
Harry Thomasian Jr. Chief Financial Officer of Precigen (NASDAQ:PGEN), reported the sale of 41,884 shares of common stock on May 28, 2026, as disclosed in the SEC Form 4 filing.
Transaction value
Precigen Q1 Earnings Call Highlights
Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025
